Stimulation of incretin secreting cells
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) are secreted from enteroendocrine cells in the gut and regulate physiological and homeostatic functions related to glucose control, metabolism and food intake. This review provides a systemat...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-02-01
|
Series: | Therapeutic Advances in Endocrinology and Metabolism |
Online Access: | https://doi.org/10.1177/2042018815618177 |
id |
doaj-a645cca1ba764a6e8717ad97c17ae50f |
---|---|
record_format |
Article |
spelling |
doaj-a645cca1ba764a6e8717ad97c17ae50f2020-11-25T03:51:58ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01882042-01962016-02-01710.1177/2042018815618177Stimulation of incretin secreting cellsRamona PaisFiona M. GribbleFrank ReimannThe incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) are secreted from enteroendocrine cells in the gut and regulate physiological and homeostatic functions related to glucose control, metabolism and food intake. This review provides a systematic summary of the molecular mechanisms underlying secretion from incretin cells, and an understanding of how they sense and interact with lumen and vascular factors and the enteric nervous system through transporters and G-protein coupled receptors (GPCRs) present on their surface to ultimately culminate in hormone release. Some of the molecules described below such as sodium coupled glucose transporter 1 (SGLT1), G-protein coupled receptor (GPR) 119 and GPR40 are targets of novel therapeutics designed to enhance endogenous gut hormone release. Synthetic ligands at these receptors aimed at treating obesity and type 2 diabetes are currently under investigation.https://doi.org/10.1177/2042018815618177 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ramona Pais Fiona M. Gribble Frank Reimann |
spellingShingle |
Ramona Pais Fiona M. Gribble Frank Reimann Stimulation of incretin secreting cells Therapeutic Advances in Endocrinology and Metabolism |
author_facet |
Ramona Pais Fiona M. Gribble Frank Reimann |
author_sort |
Ramona Pais |
title |
Stimulation of incretin secreting cells |
title_short |
Stimulation of incretin secreting cells |
title_full |
Stimulation of incretin secreting cells |
title_fullStr |
Stimulation of incretin secreting cells |
title_full_unstemmed |
Stimulation of incretin secreting cells |
title_sort |
stimulation of incretin secreting cells |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Endocrinology and Metabolism |
issn |
2042-0188 2042-0196 |
publishDate |
2016-02-01 |
description |
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) are secreted from enteroendocrine cells in the gut and regulate physiological and homeostatic functions related to glucose control, metabolism and food intake. This review provides a systematic summary of the molecular mechanisms underlying secretion from incretin cells, and an understanding of how they sense and interact with lumen and vascular factors and the enteric nervous system through transporters and G-protein coupled receptors (GPCRs) present on their surface to ultimately culminate in hormone release. Some of the molecules described below such as sodium coupled glucose transporter 1 (SGLT1), G-protein coupled receptor (GPR) 119 and GPR40 are targets of novel therapeutics designed to enhance endogenous gut hormone release. Synthetic ligands at these receptors aimed at treating obesity and type 2 diabetes are currently under investigation. |
url |
https://doi.org/10.1177/2042018815618177 |
work_keys_str_mv |
AT ramonapais stimulationofincretinsecretingcells AT fionamgribble stimulationofincretinsecretingcells AT frankreimann stimulationofincretinsecretingcells |
_version_ |
1724485247022661632 |